Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Feldmann

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Nature Communications|January 12, 2022
C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosisInhye Park, Michael E Goddard, Jennifer E Cole, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2015
Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug developmentJennifer E Cole, Nagore Astola, Adam P Cribbs, et al.
Annals of Neurology|September 7, 2010
Role of interleukin-1beta in postoperative cognitive dysfunctionMario Cibelli, Antonio Rei Fidalgo, Niccolò Terrando, et al.
The Lancet. Rheumatology|August 11, 2022
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trialJagdeep Nanchahal, Catherine Ball, Ines Rombach, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic targetLiaquat S Verjee, Jennifer S N Verhoekx, James K K Chan, et al.
Nature Reviews. Drug Discovery|February 28, 2015
Preclinical target validation using patient-derived cellsAled M Edwards, Cheryl H Arrowsmith, Chas Bountra, et al.
Journal of the American Society of Nephrology : JASN|February 23, 2007
Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6Abdulmunem Sheryanna, Gurjeet Bhangal, John McDaid, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2011
Unexpected protective role for Toll-like receptor 3 in the arterial wallJennifer E Cole, Tina J Navin, Amanda J Cross, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 24, 2004
A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritisJamie Campbell, Cathleen J Ciesielski, Abigail E Hunt, et al.
Rheumatology (Oxford, England)|October 10, 2009
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritisPhilippa Hillyer, Maggie J Larché, Edward P Bowman, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Nature Communications|January 12, 2022
C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosisInhye Park, Michael E Goddard, Jennifer E Cole, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2015
Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug developmentJennifer E Cole, Nagore Astola, Adam P Cribbs, et al.
Annals of Neurology|September 7, 2010
Role of interleukin-1beta in postoperative cognitive dysfunctionMario Cibelli, Antonio Rei Fidalgo, Niccolò Terrando, et al.
The Lancet. Rheumatology|August 11, 2022
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trialJagdeep Nanchahal, Catherine Ball, Ines Rombach, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic targetLiaquat S Verjee, Jennifer S N Verhoekx, James K K Chan, et al.
Nature Reviews. Drug Discovery|February 28, 2015
Preclinical target validation using patient-derived cellsAled M Edwards, Cheryl H Arrowsmith, Chas Bountra, et al.
Journal of the American Society of Nephrology : JASN|February 23, 2007
Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6Abdulmunem Sheryanna, Gurjeet Bhangal, John McDaid, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2011
Unexpected protective role for Toll-like receptor 3 in the arterial wallJennifer E Cole, Tina J Navin, Amanda J Cross, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 24, 2004
A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritisJamie Campbell, Cathleen J Ciesielski, Abigail E Hunt, et al.
Rheumatology (Oxford, England)|October 10, 2009
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritisPhilippa Hillyer, Maggie J Larché, Edward P Bowman, et al.
Pageof 16